COVID-19: PeaceHealth is open, with safe virtual and in-person visits.
Learn more about our safety measures and visitor restrictions.

Breast

  • A011401 Breast Cancer WEight Loss Study (BWEL Study):  Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
  • A011502 Aspirin in Preventing Recurrence of Cancer in Patients with HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
  • NRG-BR003 Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel with or Without Carboplatin in Treating Patients with Triple-Negative Breast Cancer
  • NRG-BR004   A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First Line HER2-Positive Metastatic Breast Cancer
  • EA1131 Platinum Based Chemotherapy or Capecitabine in Treating Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
  • EAZ171 Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy Induced Peripheral Neuropathy in African American Women with stage I-III breast cancer
  • S1418 A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy
  • S1501 Carvedilol in Preventing Cardiac Toxicity in Patients with Metastatic HER-2-Positive Breast Cancer
  • S1703  Serum Tumor marker Directed Disease Monitoring in patients with Hormone Receptor positive HER2 Negative Metastatic Breast Cancer
  • URCC-18007 Randomized Placebo Controlled Trial of Bupropion for Cancer Related Fatigue in stage I-III breast cancer survivors
  • EA1181 (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)